TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39231871

Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 39231898

Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7) infusion at 10 mcg/Kg day for a maximum of 7 days (Phase 2)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 107
Study: 39232249

Group type: EXPERIMENTAL
Intervention: Exercise-Based Injury Prevention Program (EIPP)
Number of subjects: 840
Study: 39232261

Group type: EXPERIMENTAL
Intervention: AI-based rapid nutritional diagnostic system
Number of subjects: 5763

Group type: COMPARATOR
Intervention: Control (no AI-based assessment)
Number of subjects: 5763
Study: 39232408

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (nab-P) 100 mg/m² on days 1 and 8, carboplatin (C) on day 1, every 3 weeks for 6 cycles
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (nab-P) and carboplatin (C)
Number of subjects: 23
Study: 39232460

Group type: EXPERIMENTAL
Intervention: Outpatient induction of labour methods
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: New technologies of induction
Number of subjects: 27
Study: 39232496

Group type: EXPERIMENTAL
Intervention: CMG901 (Claudin18.2-specific antibody-drug conjugate)
Number of subjects: 0
Study: 39232601

Group type: EXPERIMENTAL
Intervention: Combined low MUAC and low WHZ
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low MUAC-only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low WHZ-only
Number of subjects: 0
Study: 39232602

Group type: EXPERIMENTAL
Intervention: Spirulina (1 g twice daily for 14 days)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Spirulina
Number of subjects: 1126
Study: 39232634

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 to 150 mg every 2 weeks subcutaneously
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 39232667

Group type: EXPERIMENTAL
Intervention: Digital movement and music intervention (12 weeks, 3 sessions per week: 2 movement and music sessions, 1 music-only session)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Digital movement and music intervention
Number of subjects: 34
Study: 39232668

Group type: EXPERIMENTAL
Intervention: Shared meditation (4 mixed groups of 8 patients, 4 health professionals, and 4 third parties)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Patient meditation (2 groups of 16 patients)
Number of subjects: 96
Study: 39232703

Group type: EXPERIMENTAL
Intervention: US-guided extraoral mandibular nerve block
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intraoral inferior alveolar nerve block
Number of subjects: 36
Study: 39232708

Group type: EXPERIMENTAL
Intervention: Neck Stabilization Exercises (NSE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dynamic Exercises (NDE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: NSE
Number of subjects: 60

Group type: COMPARATOR
Intervention: NDE
Number of subjects: 60
Study: 39232732

Group type: EXPERIMENTAL
Intervention: Open-space offices
Number of subjects: 175688

Group type: EXPERIMENTAL
Intervention: Long-distance trains
Number of subjects: 175688

Group type: EXPERIMENTAL
Intervention: Convenience stores
Number of subjects: 175688

Group type: EXPERIMENTAL
Intervention: Take-away delivery
Number of subjects: 175688

Group type: EXPERIMENTAL
Intervention: Car-pooling with relatives
Number of subjects: 175688

Group type: EXPERIMENTAL
Intervention: Taxis
Number of subjects: 175688

Group type: EXPERIMENTAL
Intervention: Airplanes
Number of subjects: 175688

Group type: EXPERIMENTAL
Intervention: Concerts
Number of subjects: 175688

Group type: EXPERIMENTAL
Intervention: Night-clubs
Number of subjects: 175688

Group type: EXPERIMENTAL
Intervention: Bars and restaurants
Number of subjects: 175688

Group type: COMPARATOR
Intervention: Short-distance shared transport, car-pooling booked over platforms, markets, supermarkets and malls, hairdressers, museums, movie theatres, outdoor sports, swimming pools
Number of subjects: 175688
Study: 39232748

Group type: COMPARATOR
Intervention: Paleolithic diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diabetes diet
Number of subjects: 13
Study: 39232760

Group type: EXPERIMENTAL
Intervention: Shoulder massage administered twice at 6-hour intervals
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 60
Study: 39232761

Group type: EXPERIMENTAL
Intervention: Fuzuloparib 60 mg BID plus mFOLFIRINOX q2w for 8-12 cycles followed by maintenance fuzuloparib at 150 mg BID
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fuzuloparib 30 mg BID
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fuzuloparib 60 mg BID
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fuzuloparib 100 mg BID
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fuzuloparib plus mFOLFIRINOX
Number of subjects: 39
Study: 39232778

Group type: EXPERIMENTAL
Intervention: Fentanyl test strip education and distribution
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Non-intervention (no fentanyl test strip education or distribution)
Number of subjects: 2400
Study: 39232779

Group type: EXPERIMENTAL
Intervention: Salt substitute
Number of subjects: 20995

Group type: COMPARATOR
Intervention: Regular salt
Number of subjects: 20995
Study: 39232781

Group type: EXPERIMENTAL
Intervention: Omentum preservation during gastrectomy
Number of subjects: 654

Group type: COMPARATOR
Intervention: Complete omentectomy during gastrectomy
Number of subjects: 654
Study: 39232792

Group type: EXPERIMENTAL
Intervention: Multicomponent physical training programme (progressive and supervised endurance, resistance and balance training for 4 weeks, twice weekly sessions, total of 8 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicomponent physical training programme
Number of subjects: 0
Study: 39232795

Group type: EXPERIMENTAL
Intervention: Conventional lung protective ventilation plus sigh volumes producing plateau pressures of 35 cmH2O
Number of subjects: 192

Group type: COMPARATOR
Intervention: Conventional lung protective ventilation
Number of subjects: 192
Study: 39232840

Group type: EXPERIMENTAL
Intervention: Polyurethane A
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Polyurethane B
Number of subjects: 300

Group type: COMPARATOR
Intervention: Latex C
Number of subjects: 300
Study: 39232999

Group type: EXPERIMENTAL
Intervention: Adjunctive pneumatic compression
Number of subjects: 2003

Group type: COMPARATOR
Intervention: Risk assessment models (Caprini, Padua, Intermountain, ICU-VTE, Kucher, IMPROVE)
Number of subjects: 2003
Study: 39233015

Group type: EXPERIMENTAL
Intervention: Busulfan-based hematopoietic cell transplantation (HCT) with PT/Cy for GVHD prophylaxis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Busulfan-based HCT with PT/Cy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PT/Cy for GVHD prophylaxis
Number of subjects: 36
Study: 39233117

Group type: EXPERIMENTAL
Intervention: STRONGkids tool (high risk)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: STRONGkids tool (moderate risk)
Number of subjects: 345

Group type: COMPARATOR
Intervention: AAIMp tool (mild, moderate, severe malnutrition)
Number of subjects: 345
Study: 39233210

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg daily
Number of subjects: 2770

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2770
Study: 39233211

Group type: EXPERIMENTAL
Intervention: High LVEF (>65%)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Normal LVEF (55%-65%)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Low EF (<55%)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Age comparison
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: LV cavity volume
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: LV mass-volume ratio
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: LV end-systolic elastance
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Myocardial perfusion reserve index (MPRI)
Number of subjects: 370
Study: 39233312

Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg once daily
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Belzutifan 200 mg once daily
Number of subjects: 154
Study: 39233711

Group type: EXPERIMENTAL
Intervention: Fostemsavir + optimized background therapy
Number of subjects: 272
Study: 39233850

Group type: EXPERIMENTAL
Intervention: TAU plus Mindful Journey
Number of subjects: 34

Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 34
Study: 39233999

Group type: EXPERIMENTAL
Intervention: Ocular lubricants, used four times a day for 30 days
Number of subjects: 173
Study: 39234256

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC; daratumumab plus pomalidomide and dexamethasone [DPd] or pomalidomide plus bortezomib and dexamethasone [PVd])
Number of subjects: 0
Study: 39234416

Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg each) administered subcutaneously every 4 weeks (n=9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 20
Study: 39234619

Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 41

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 41
Study: 39234862

Group type: EXPERIMENTAL
Intervention: Acalabrutinib, bendamustine, and rituximab (ABR) in TN cohort
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Acalabrutinib, bendamustine, and rituximab (ABR) in R/R cohort
Number of subjects: 38
Study: 39234997

Group type: EXPERIMENTAL
Intervention: Adapted CARING intervention for rural cancer caregivers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: enCompass intervention
Number of subjects: 10
Study: 39235326

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (12 cycles)
Number of subjects: 179

Group type: COMPARATOR
Intervention: FOLFIRINOX (8 cycles) followed by LV5FU2 maintenance
Number of subjects: 179
Study: 39235488

Group type: EXPERIMENTAL
Intervention: AHNAK1/2-mutant ESCC
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Knockdown of AHNAK in ESCC cell lines
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Two-gene signature
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Molecular classification scheme
Number of subjects: 201
Study: 39235513

Group type: EXPERIMENTAL
Intervention: sodium hypochlorite/amino acid gel and crosslinked hyaluronic acid (xHyA) with subgingival instrumentation
Number of subjects: 52

Group type: COMPARATOR
Intervention: subgingival instrumentation alone
Number of subjects: 52
Study: 39235596

Group type: EXPERIMENTAL
Intervention: Sitravatinib monotherapy
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Sitravatinib plus tislelizumab
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sitravatinib monotherapy and sitravatinib plus tislelizumab
Number of subjects: 111
Study: 39235639

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) shock microcycles with a focus on time spent in zone 3 (Z3) or the 'red zone'.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart rate-based training decisions during HIIT-SM.
Number of subjects: 0
Study: 39235772

Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg daily for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo daily for 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 39235816

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty plus aggressive medical management (n=249)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Aggressive medical management alone (n=252)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty plus aggressive medical management
Number of subjects: 512

Group type: COMPARATOR
Intervention: Aggressive medical management alone
Number of subjects: 512
Study: 39235836

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention (EMI) program designed to replace sitting time with physical activity for 6 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Physical activity guidelines education (Control)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention (EMI) program
Number of subjects: 39
Study: 39235853

Group type: EXPERIMENTAL
Intervention: SteWARdS Antibiotic Defence app (intervention group)
Number of subjects: 348

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 348
Study: 39235855

Group type: EXPERIMENTAL
Intervention: POSTHOC app (digital SCP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care (paper-based SCP)
Number of subjects: 54
Study: 39235870

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39235931

Group type: EXPERIMENTAL
Intervention: Full DSME programme
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 60% completion of DSME programme
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10% completion of DSME programme
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0% completion of DSME programme (delayed education)
Number of subjects: 120
Study: 39236047

Group type: EXPERIMENTAL
Intervention: 5-mm introducer retraction before marker deployment
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard marker placement
Number of subjects: 223
Study: 39236052

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall SMART DAPPER intervention
Number of subjects: 20
Study: 39236057

Group type: EXPERIMENTAL
Intervention: ADFICE_IT clinical decision support system (CDSS) for deprescribing FRIDs
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Usability testing of the CDSS
Number of subjects: 581

Group type: COMPARATOR
Intervention: Cluster-randomized controlled trial of the CDSS
Number of subjects: 581
Study: 39236063

Group type: EXPERIMENTAL
Intervention: Fear of Activity in Situations-Heart Failure (FActS-HF15) questionnaire
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Attention towards cardiac symptoms and symptom distress
Number of subjects: 185
Study: 39236080

Group type: EXPERIMENTAL
Intervention: Teacher-Led intervention
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Teacher fidelity
Number of subjects: 744

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Researcher-Led intervention
Number of subjects: 744
Study: 39236218

Group type: EXPERIMENTAL
Intervention: Evusheld
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 39236276

Group type: EXPERIMENTAL
Intervention: Inavolisib + Palbociclib + Letrozole
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Inavolisib + Palbociclib + Fulvestrant
Number of subjects: 53
Study: 39236320

Group type: EXPERIMENTAL
Intervention: First-trimester Hb A 1C levels
Number of subjects: 1908

Group type: COMPARATOR
Intervention: Psychiatric disorders prevalence
Number of subjects: 1908

Group type: COMPARATOR
Intervention: Thyroid disorders prevalence
Number of subjects: 1908

Group type: COMPARATOR
Intervention: Folic acid supplementation prevalence
Number of subjects: 1908
Study: 39236727

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty with the option of rescue stenting (DCB group)
Number of subjects: 2272

Group type: COMPARATOR
Intervention: Intended deployment of second-generation thin-strut sirolimus-eluting stents (DES group)
Number of subjects: 2272
Study: 39236729

Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 1604

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1604
Study: 39236733

Group type: EXPERIMENTAL
Intervention: Casirivimab and imdevimab (150-1200 mg intravenously or 600-1200 mg subcutaneously) administered before or at the same time as mRNA-1273 vaccination
Number of subjects: 295

Group type: COMPARATOR
Intervention: mRNA-1273 only
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Casirivimab and imdevimab plus mRNA-1273
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Casirivimab and imdevimab administered 48 mg and 12 mg intravenously
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: mRNA-1273 administered 6 days before mAb
Number of subjects: 295
Study: 39236736

Group type: EXPERIMENTAL
Intervention: 10 mg/kg infliximab
Number of subjects: 138

Group type: COMPARATOR
Intervention: 5 mg/kg infliximab
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: IIS (10 mg/kg infliximab)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: AIS (5 mg/kg infliximab, accelerated induction)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: SIS (5 mg/kg infliximab, standard induction)
Number of subjects: 138
Study: 39236780

Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactate clamp procedure
Number of subjects: 0
Study: 39236781

Group type: EXPERIMENTAL
Intervention: Nutrition360 intervention
Number of subjects: 31
Study: 39236984

Group type: EXPERIMENTAL
Intervention: Isotoxically dose-escalated chemoradiotherapy (60-74 Gy in 30-37 fractions)
Number of subjects: 172

Group type: COMPARATOR
Intervention: PET-based selective nodal irradiation
Number of subjects: 172
Study: 39237070

Group type: EXPERIMENTAL
Intervention: Atrial shunt treatment
Number of subjects: 665

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Shunt treatment
Number of subjects: 665
Study: 39237101

Group type: EXPERIMENTAL
Intervention: Sertoli cells from Klinefelter syndrome (KS) patients cultured for 60 days in DMEM medium containing FBS
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sertoli cells from control (46,XY) patients cultured for 60 days in DMEM medium containing FBS
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sertoli cells from Klinefelter syndrome (KS) patients
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sertoli cells from control (46,XY) patients
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Functional proteins and gene expressions (GDNF, BMP4, AR, CLDN11) in KS SCs
Number of subjects: 6

Group type: COMPARATOR
Intervention: Functional proteins and gene expressions (GDNF, BMP4, AR, CLDN11) in control SCs
Number of subjects: 6
Study: 39237135

Group type: EXPERIMENTAL
Intervention: Product A (iso-osmolar dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Product B (iso-osmolar escalation dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Product C (hypo-osmolar escalation dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline douche of matching osmolarity
Number of subjects: 18
Study: 39237149

Group type: EXPERIMENTAL
Intervention: Posterior quadratus lumborum block
Number of subjects: 104

Group type: COMPARATOR
Intervention: Intrathecal morphine
Number of subjects: 104
Study: 39237158

Group type: EXPERIMENTAL
Intervention: Gated 18F-fluorodeoxyglucose positron emission tomography coupled with computed tomography (FDG PET/CT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard CT scan with intravenous contrast
Number of subjects: 84
Study: 39237263

Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study: 39237273

Group type: EXPERIMENTAL
Intervention: Digital therapy programme using a smartphone application based on individual health data, duration of 180 days (90-day in-life phase followed by a 90-day follow-up phase).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care for the treatment of primary arterial hypertension, duration of 180 days.
Number of subjects: 0
Study: 39237276

Group type: EXPERIMENTAL
Intervention: Digital tool for genetic cancer risk assessment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (clinician interview for genetic cancer risk assessment)
Number of subjects: 100
Study: 39237277

Group type: EXPERIMENTAL
Intervention: AI-assisted image analysis
Number of subjects: 500

Group type: COMPARATOR
Intervention: Traditional diagnostic methods
Number of subjects: 500
Study: 39237284

Group type: EXPERIMENTAL
Intervention: Hyperangulated VL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macintosh VL (control group)
Number of subjects: 0
Study: 39237283

Group type: EXPERIMENTAL
Intervention: Standardised intervention for announcing decisions of withholding or withdrawing life-sustaining treatments
Number of subjects: 538

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 538
Study: 39237321

Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride (Kuvan®)
Number of subjects: 576
Study: 39237427

Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg orally daily from days 1 to 21; Daratumumab 16 mg/kg intravenously on specified days; Dexamethasone 40 mg (age ≤ 75 years) or 20 mg (age > 75 years) orally on specified days.
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pomalidomide, Dexamethasone, Daratumumab
Number of subjects: 112
Study: 39237545

Group type: EXPERIMENTAL
Intervention: Blastocyst-stage single embryo transfer
Number of subjects: 992

Group type: COMPARATOR
Intervention: Cleavage-stage single embryo transfer
Number of subjects: 992
Study: 39237725

Group type: EXPERIMENTAL
Intervention: Home-based exercise prehabilitation plus nutritional guidance
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Complier average causal effects for home-based exercise prehabilitation
Number of subjects: 204
Study: 39237780

Group type: EXPERIMENTAL
Intervention: Effort Re-education Programme
Number of subjects: 170

Group type: COMPARATOR
Intervention: Conventional Clinical Practice
Number of subjects: 170
Study: 39237867

Group type: EXPERIMENTAL
Intervention: FASTRACS intervention (4 steps over 6 months)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: FASTRACS intervention
Number of subjects: 420
Study: 39237936

Group type: EXPERIMENTAL
Intervention: In-person delivery of ECD parenting intervention
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Hybrid-delivery model (remote mHealth delivery via smartphones)
Number of subjects: 1200